Monitoring by three laboratory methods of an oral GPIIb/IIIa anti-platelet agent in patients with vascular disease

被引：0
|
作者：
Ledford, MR
Canton, M
Preston, R
Gretler, DD
Enten, J
Alonso, A
Brito, MI
Delgado, L
Mitchell, M
机构：
[1] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33152 USA
[2] Univ Miami, Sch Med, Dept Clin Pharmacol, Miami, FL 33152 USA
[3] Biocytex, Miami, FL USA
[4] COR Therapeut Inc, Marseille, France
[5] Beckman Coulter Corp, S San Francisco, CA USA
来源：
THROMBOSIS AND HAEMOSTASIS | 1999年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2601
引用
收藏
页码：821 / 821
页数：1
相关论文
共 50 条
  • [41] Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty
    Ahnadi, CE
    Boughrassa, FF
    Chapman-Montgomery, ES
    Poisson, W
    Gervais, A
    Okrongly, D
    Grant, AM
    THROMBOSIS AND HAEMOSTASIS, 2004, 92 (06) : 1207 - 1213
  • [42] VASCULAR AND ANTI-PLATELET ACTIONS OF INTERMITTENT INFUSION WITH A NEW STABLE PROSTACYCLIN DERIVATIVE IN PATIENTS WITH RAYNAUD PHENOMENON AND SCLERODERMA
    KELLER, J
    KALTENECKER, A
    KRAIS, T
    HORNSTEIN, OP
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 1985, 277 (05) : 426 - 427
  • [43] Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy
    Caliandro, Pietro
    EUROPEAN STROKE JOURNAL, 2023, 8 (03) : 722 - 730
  • [44] Anti-platelet factor 4/heparin antibody is associated with progression of peripheral arterial disease in hemodialysis patients
    Chen, Yen-Hsun
    Lin, Kao-Chang
    Tsai, Yueh-Feng
    Yu, Lai-King
    Huang, Li-Hsueh
    Chen, Chien-An
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (09) : 1565 - 1570
  • [45] The use of roxifiban, a novel oral IIb/IIIa platelet inhibitor, in patients with stable coronary artery disease
    Gussak, I
    Murphy, J
    Daly, R
    Wright, RS
    Cornwell, K
    Williams, B
    Wilcox, RA
    Kopecky, SL
    EUROPEAN HEART JOURNAL, 2000, 21 : 648 - 648
  • [46] Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
    Kitrou, Panagiotis
    Katsanos, Konstantinos
    Karnabatidis, Dimitris
    Reppas, Lazaros
    Brountzos, Elias
    Spiliopoulos, Stavros
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (05) : 430 - 445
  • [47] Role of reticulated platelets and platelet size in modifying anti-platelet effects of aspirin and clopidogrel in patients with stable coronary artery disease
    Alviar, Carlos L.
    Vaduganathan, Muthiah
    Tellez, Armando
    Rammohan, Karthik
    Nure, Bahru
    Delao, Timothy
    Arikan, Mehmet
    Granada, Juan F.
    Lev, Eli I.
    Kleiman, Neal S.
    Guthikonda, Sasidhar
    CIRCULATION RESEARCH, 2007, 101 (11) : 1210 - 1210
  • [48] HDL-Cholesterol serves as a powerful predictor of platelet activation in patients with coronary heart disease on dual anti-platelet therapy
    Jaeger, B.
    Andric, T.
    Piackova, E.
    Wojta, J.
    Huber, K.
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S302 - S302
  • [49] Anti-platelet factor 4/heparin antibody is associated with progression of peripheral arterial disease in hemodialysis patients
    Yen-Hsun Chen
    Kao-Chang Lin
    Yueh-Feng Tsai
    Lai-King Yu
    Li-Hsueh Huang
    Chien-An Chen
    International Urology and Nephrology, 2015, 47 : 1565 - 1570
  • [50] A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti-Platelet Activation Membrane Dialyzer in Hemodialysis Patients
    Kakuta, Takatoshi
    Ishida, Mari
    Komaba, Hirotaka
    Suzuki, Hajime
    Fukagawa, Masafumi
    THERAPEUTIC APHERESIS AND DIALYSIS, 2019, 23 (02) : 133 - 144
12345